Literature DB >> 12496317

Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.

S Jain1, A G Bhojwani, J K Mellon.   

Abstract

Prostate specific antigen (PSA) testing is now a routine part of the investigation of men with suspected prostate cancer. While a very useful test it still has its problems, in particular its lack of specificity means abnormal results are often caused by benign disease. This review describes the current problems with PSA testing in prostate cancer diagnosis and highlights potential ways in which these may be reduced.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12496317      PMCID： PMC1742550          DOI： 10.1136/pmj.78.925.646

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  50 in total

1.  Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.

Authors:  M L Beckett; L H Cazares; A Vlahou; P F Schellhammer; G L Wright
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

2.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

3.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

4.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 5.  Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction.

Authors:  S L Su; A L Boynton; E H Holmes; A A Elgamal; G P Murphy
Journal:  Semin Surg Oncol       Date:  2000 Jan-Feb

6.  Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.

Authors:  A W Partin; W J Catalona; J A Finlay; C Darte; D J Tindall; C Y Young; G G Klee; D W Chan; H G Rittenhouse; R L Wolfert; D L Woodrum
Journal:  Urology       Date:  1999-11       Impact factor: 2.649

7.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.

Authors:  Z Xiao; B L Adam; L H Cazares; M A Clements; J W Davis; P F Schellhammer; E A Dalmasso; G L Wright
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

8.  Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.

Authors:  T A Stamey; C E Yemoto
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

9.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

10.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.

Authors:  D S Smith; W J Catalona
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450
View more
  5 in total

1.  [Significance of the PSA-concentration for the detection of prostate cancer].

Authors:  A Stachon
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

2.  Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.

Authors:  Rachel A Levin; Maria E Lund; Quach Truong; Angela Wu; Neal D Shore; Daniel R Saltzstein; Raoul S Concepcion; Thomas A Paivanas; Arletta van Breda; Jennifer Beebe-Dimmer; Julie J Ruterbusch; Sandra Wissmueller; Douglas H Campbell; Bradley J Walsh
Journal:  Oncotarget       Date:  2018-04-27

3.  Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men.

Authors:  George A Dominguez; Alexander T Polo; John Roop; Anthony J Campisi; Robert A Somer; Adam D Perzin; Dmitry I Gabrilovich; Amit Kumar
Journal:  Biomark Insights       Date:  2020-04-17

4.  A Prostate Cancer Proteomics Database for SWATH-MS Based Protein Quantification.

Authors:  Ammara Muazzam; Davide Chiasserini; Janet Kelsall; Nophar Geifman; Anthony D Whetton; Paul A Townsend
Journal:  Cancers (Basel)       Date:  2021-11-08       Impact factor: 6.639

Review 5.  Extended and saturation needle biopsy for the diagnosis of prostate cancer.

Authors:  Kristin L Chrouser; Michael M Lieber
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.